Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$11.29
+0.3%
$12.65
$10.45
$21.69
$3.99B0.58669,789 shs559,805 shs
Paragon 28, Inc. stock logo
FNA
Paragon 28
$13.11
+0.1%
$13.07
$4.65
$13.13
$1.10B1.471.12 million shs19.38 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$76.89
+4.1%
$68.88
$36.93
$80.99
$3.87B-2.67749,080 shs474,984 shs
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$124.25
+0.7%
$89.57
$55.00
$177.37
$4.20B1.911.36 million shs443,082 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.00%-4.10%-18.80%-28.31%-23.17%
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.00%0.00%0.00%+0.69%+66.62%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%+2.51%+3.58%+66.68%+79.36%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
0.00%+2.20%+31.93%+72.69%-9.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
4.1221 of 5 stars
4.14.00.00.02.10.03.8
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
4.8386 of 5 stars
4.64.00.04.63.03.30.6
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
1.2903 of 5 stars
1.41.00.00.02.92.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
2.25
Hold$15.5037.33% Upside
Paragon 28, Inc. stock logo
FNA
Paragon 28
2.20
Hold$12.75-2.71% Downside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3.11
Buy$106.7838.87% Upside
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.82
Moderate Buy$126.701.97% Upside

Current Analyst Ratings Breakdown

Latest FNA, BLCO, TMDX, and SLNO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.00
5/9/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$81.00 ➝ $97.00
5/8/2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$102.00 ➝ $105.00
5/6/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$18.00 ➝ $12.00
5/2/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $15.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$14.00 ➝ $13.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $12.00
5/1/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$19.00 ➝ $15.50
4/29/2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$90.00 ➝ $105.00
4/24/2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$4.83B0.83$1.34 per share8.41$18.57 per share0.61
Paragon 28, Inc. stock logo
FNA
Paragon 28
$256.18M4.29N/AN/A$2.05 per share6.39
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/A$5.16 per shareN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$488.23M8.61$0.23 per share530.08$4.20 per share29.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
-$317M-$1.03N/A11.760.85-6.62%3.35%1.66%7/30/2025 (Estimated)
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$57.53M-$0.63N/AN/AN/A-25.31%-37.90%-18.22%N/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$38.99M-$4.62N/AN/AN/AN/A-61.99%-55.21%8/6/2025 (Estimated)
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
-$25.03M$1.36132.1886.89N/A8.14%18.74%4.39%7/30/2025 (Estimated)

Latest FNA, BLCO, TMDX, and SLNO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
$0.29$0.70+$0.41$0.70$123.39 million$143.54 million
5/7/2025Q1 2025
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$1.14-$0.95+$0.19-$0.95N/AN/A
4/30/2025Q1 2025
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
$0.03-$0.07-$0.10-$0.60$1.15 billion$1.15 billion
3/6/2025Q4 2024
Paragon 28, Inc. stock logo
FNA
Paragon 28
-$0.12-$0.13-$0.01-$0.13$70.81 million$71.75 million
3/5/2025Q4 2024
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
-$0.86-$1.27-$0.41-$1.27N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Paragon 28, Inc. stock logo
FNA
Paragon 28
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.72
1.60
1.01
Paragon 28, Inc. stock logo
FNA
Paragon 28
0.79
3.50
1.60
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/A
17.26
17.26
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
2.42
8.20
7.33

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
11.07%
Paragon 28, Inc. stock logo
FNA
Paragon 28
63.57%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
99.67%

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
0.76%
Paragon 28, Inc. stock logo
FNA
Paragon 28
15.32%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
12.30%
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
7.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Co. stock logo
BLCO
Bausch + Lomb
12,500353.43 million351.94 millionOptionable
Paragon 28, Inc. stock logo
FNA
Paragon 28
343,00083.94 million70.89 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3050.39 million37.81 millionOptionable
TransMedics Group, Inc. stock logo
TMDX
TransMedics Group
21033.82 million31.21 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$11.29 +0.04 (+0.33%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$11.30 +0.01 (+0.12%)
As of 05/23/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Paragon 28 stock logo

Paragon 28 NYSE:FNA

$13.10 +0.02 (+0.11%)
Closing price 04/17/2025
Extended Trading
$13.10 0.00 (0.00%)
As of 04/17/2025 05:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Paragon 28, Inc. develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; APEX 3D total ankle replacement systems; and total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides forefoot or hallux valgus correction systems, including phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

$76.89 +3.00 (+4.06%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$76.86 -0.03 (-0.03%)
As of 05/23/2025 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

TransMedics Group stock logo

TransMedics Group NASDAQ:TMDX

$124.25 +0.91 (+0.74%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$122.84 -1.41 (-1.14%)
As of 05/23/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.